Dormacy in Cancer and Tumor Cells
Published: 2023-05-31
Page: 119-127
Issue: 2023 - Volume 6 [Issue 1]
Ikalo David Oseghale *
Department of Biochemistry, Faculty of Life Sciences, University of Benin, Nigeria.
Godwin Mmaduabuchi Ikokwu
Faculty of Pharmacy, University of Benin, Nigeria.
Imade Omoregie
Department of Biochemistry, Faculty of Life Sciences, University of Benin, Nigeria.
*Author to whom correspondence should be addressed.
Abstract
The phenomenon of dormancy in cancer and tumor cells is defined by the halting of cell division and the preservation of a dormant or slow-growing condition. Cells can stay in this state long after the underlying tumor has been excised or after surveillance and therapeutic intervention, and it can endure for years or even decades. During the course of a cancer, cancer cells are likely to spread, and some may go into dormancy, remaining alive but not multiplying. With today's diagnostic tools, it is extremely rare to find these latent cancer cells (DCCs). Additionally, they are able to decipher homoeostatic signals from the microenvironment to avoid immune monitoring and treatment. DCCs may eventually reawaken in response to not recognized signals, which would cause recurrence and metastasis. Therefore, avoiding metastasis requires an understanding of the biology of DCC reawakening. Chronic inflammation can revive cancer proliferation in distant places, and immune cells' cytotoxic activities can put cancer cells into a latent condition. Circulating DCCs bind to extracellular molecules, activating a number of signaling cascades and resuming cell growth. Recent research has revealed that dormant cells can reactivate and develop metastatic illness, which is the main factor contributing to cancer-related mortality. Therefore, it is essential to comprehend the variables that control dormancy and reactivation in order to create efficient methods to stop the spread of metastatic illness. In summary, dormancy in cancer and tumor cells is a complicated and poorly understood phenomena that is crucial to the development and metastasis of cancer. To understand the mechanisms that control dormancy and to create efficient therapeutic approaches to stop cancer development and metastasis, more research is required.The objective of this review article is to provide a valuable and critical summary of the area of dormancy in cancer and tumor cells. Articles used in this review were sourced from websites like researchgate, Elsevier, etc using keywords like cancer, dormancy, tumor, etc.
Keywords: Cancer, tumor, dormancy, cells, cellular, metastasis
How to Cite
Downloads
References
Miller AK, Brown JS, Enderling H, Basanta D, Whelan CJ. The evolutionary ecology of dormancy in nature and in cancer. Front. Ecol. Evol. 2021;9:676802. DOI: 10.3389/fevo.2021.676802
Tamamouna V, Pavlou E, Neophytou CM, Papageorgis P, Costeas P. Regulation of metastatic tumor dormancy and emerging opportunities for therapeutic intervention. Int J Mol Sci. 2022;23(22):13931.
Min HY, Lee HY. Cellular dormancy in cancer - mechanisms and potential targeting strategies. Cancer Res Treat. Epub ahead of Print; 2023. DOI: 10.4143/crt.2023.468 PMID: 36960624
Chauvistré H, Shannan B, Daignault Mill SM, Ju RJ, Picard D et al. Persister state-directed transitioning and vulnerability in melanoma. Nat Commun. 2022;13(1): 3055.
Preciado JA, Aksan A. Method to isolate dormant cancer cells from heterogeneous populations. Methods Mol Biol. 2022;2394:19-29.
Gu Y, Bui T, Muller WJ. Exploiting mouse models to recapitulate clinical tumor dormancy and recurrence in breast cancer. Endocrinology. 2022;163(6): bqac055.
Damen MPF, van Rheenen J, Scheele C. Targeting dormant tumor cells to prevent cancer recurrence. FEBS J. 2021;288: 6286-303.
Basu S, Dong Y, Kumar R, Jeter C, Tang DG. Slow-cycling (dormant) cancer cells in therapy resistance, cancer relapse and metastasis. Semin Cancer Biol. 2022;78: 90-103.
Santos-de-Frutos K, Djouder N. When dormancy fuels tumour relapse. Commun Biol. 2021;4:747.
Endo H, Inoue M. Dormancy in cancer. Cancer Science. 2019;110:474–480.
Almog N. Genes and regulatory pathways involved in persistence of dormant micro-tumors. Adv. Exp. Med. Biol. 2013;734: 3–17.
Giuriato S, Ryeom S, Fan AC, Bachireddy P, Lynch RC et al. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci USA. 2006;103(44):16266-71.
Eyles J, Puaux AL, Wang X, Toh B, Prakash C et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest. 2010;120(6): 2030-2039.
Liang H, Deng L, Chmura S, Burnette B, Liadis N et al. Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. J Immunol. 2013;190(11):5874-81.
Wang HF, Wang SS, Huang MC, Liang XH, Tang YJ, Tang YL. Targeting immune-mediated dormancy: a promising treatment of cancer. Front Oncol. 2019;9:498.
Gillies RJ, Brown JS, Anderson ARA, Gatenby RA. Ecoevolutionary causes and consequences of temporal changes in intratumoural blood flow. Nat. Rev. Cancer 2018;18:576–585.
Park SY, Nam JS. The force awakens: Metastatic dormant cancer cells. Experimental & Molecular Medicine. 2020; 52(4):569–581.
Borriello L, Coste A, Traub B, Sharma VP, Karagiannis GS, Lin Y et al. Primary tumor associated macrophages activate programs of invasion and dormancy in disseminating tumor cells. Nature Communications, 2022;13(1):626.
Famta P, Shah S, Khatri DK, Guru SK, Singh SB, Srivastava S. Enigmatic role of exosomes in breast cancer progression and therapy. Life Science. 2022;289: 120210.
Attaran S, Bissell MJ. The role of tumor microenvironment and exosomes in dormancy and relapse. Seminars inCancer Biology. 2022;78:35–44.
Francescangeli F, De Angelis ML, Rossi R, Cuccu A, Giuliani A, et al. Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution. Cancer Metastasis Rev. 2023;42(1):197-215.
Ohta Y, Fujii M, Takahashi S, Takano A, Nanki K, Matano M et al. Cell-matrix interface regulates dormancy in human colon cancer stem cells. Nature. 2022; 608(7924):784–794.
Sinha G, Ferrer AI, Moore CA, Naaldijk Y, Rameshwar P. Gap junctions and breast cancer dormancy. TrendsCancer. 2020; 6(4):348–357.
Baldominos P, Barbera-Mourelle A, Barreiro O, Huang Y, Wight A et al. Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche. Cell. 2022;185(10):1694-1708.
La Belle Flynn A, Calhoun BC, Sharma A, Chang JC, Almasan A, Schiemann WP. Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3 expression. Nat Commun. 2019;10(1):3668.
Akkoc Y, Peker N, Akcay A, Gozuacik D. Autophagy and cancer dormancy. Front. Oncol. 2021;11:627023.
Vera-Ramirez L, Hunter KW. Tumor cell dormancy as an adaptive cell stress response mechanism. F1000Res. 2017;6: 2134.
Sutton MN, Yang H, Huang GY, Fu C, Pontikos M et al. RAS-related GTPases DIRAS1 and DIRAS2 induce autophagic cancer cell death and are required for autophagy in murine ovarian cancer cells. Autophagy. 2018;14(4):637-653.
Sosa MS, Bragado P, Aguirre-Ghiso JA. Mechanisms of disseminated cancer cell dormancy: An awakening field. Nat Rev Cancer. 2014;14(9):611-22.